Madison-based Exact Sciences plans on acquiring two more cancer diagnostics companies as part of its intention to become a global leader in the field.

The biomedical giant behind the at-home colorectal cancer screening test, Cologuard, announced in its quarterly earnings call this week that it is in the process of acquiring Paradigm Diagnostics, which develops screenings to help doctors determine treatment options for cancer patients, and Viomics, which conducts research in sequencing and biomarkers for early cancer detection. Both are based in Phoenix, Arizona.

“We’re really excited to have both of these businesses as part of the Exact Sciences family,” CEO Kevin Conroy said.

Exact Sciences has worked with Viomics in the past to identify biomarkers, Conroy said.

The company did not disclose the terms or cost of the acquisitions.

In July, Exact Sciences announced its plans to buy California-based Genomic Health Inc. in a $2.8 billion acquisition that closed in November.

Read the full story here.